People · Operator
Named in public records as an officer, director or promoter · active 2020–2025 · Other, Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Evommune, Inc. | — | Other | Series D+ | $267.3M | $1.0B | 2020 |
| Rivus Pharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $223.5M | $415.9M | 2022 |
| Day One Biopharmaceuticals Holding Co LLC | — | Pharmaceuticals | Series D+ | $130.0M | $3.9B | 2021 |
| Werewolf Therapeutics, Inc. | — | Pharmaceuticals | Series C | $128.2M | $2.1B | 2020 |
| Mineralys Therapeutics, Inc. | — | Pharmaceuticals | Series D+ | $118.0M | $2.4B | 2022 |
| Acrivon Therapeutics, Inc. | — | Biotechnology | Series C | $115.5M | $2.4B | 2021 |
| Bambusa Therapeutics, Inc. | — | Biotechnology | Series C | $67.4M | $375.0M | 2025 |
Derek DiRocco at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Derek DiRocco on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Cohen | 1 | 38 |
| Luke Evnin | 1 | 12 |
| Patrick Enright | 1 | 10 |
| Srinivas Akkaraju | 1 | 10 |
| Briggs Morrison | 1 | 8 |
| Christoph Westphal | 1 | 8 |
| Alon Lazarus | 1 | 7 |
| David Cordo | 1 | 6 |
| Sakae Asanuma | 1 | 6 |
| Daniel Becker | 1 | 5 |
| Daniel Hicklin | 1 | 4 |
| Ian Smith | 1 | 4 |
| Francesco De Rubertis | 1 | 4 |
| Sharon Shacham | 1 | 4 |
| Michael Gladstone | 1 | 3 |
| Robert Hopfner | 1 | 3 |
| Eugene Bauer | 1 | 3 |
| Erin Lavelle | 1 | 3 |
| John Josey | 1 | 3 |
| Adam Levy | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.